Pemvidutide
Also known as: ALT-801
Browse our Pemvidutide articles and comparisons. Start with the drug explainer for the mechanism and trial evidence, or choose a comparison below.
Profile at a glance
| Attribute | Value |
|---|---|
| Sponsor | Altimmune |
| Mechanism | Balanced 1:1 GLP-1 + glucagon dual agonist |
| Administration | Once-weekly subcutaneous injection |
| Peak weight loss | ~15.6% at 48 weeks (MOMENTUM, 2.4 mg) |
| Status | Phase 2; FDA Breakthrough Therapy for MASH (Jan 2026); Phase 3 MASH planned |
Drug explainer
What Is Pemvidutide? Altimmune's GLP-1/Glucagon Dual Agonist for Weight Loss and MASH →Altimmune’s investigational medicine has Phase 2 obesity data and an enrolling Phase 3 MASH trial; liver markers and muscle claims need careful interpretation.
See all drug profiles in the drug profiles hub or compare drugs head-to-head in the comparisons hub.